{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:22:24Z","timestamp":1780471344380,"version":"3.54.1"},"reference-count":51,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic sclerosis\u2010associated interstitial lung disease (SSc\u2010ILD) is the most frequent cause of death for SSc but there is still no sufficient treatment available. Although cyclophosphamide (CYC) therapy is a common treatment which has shown statistical efficacy against SSc\u2010ILD to date, its effects are temporary and not enough. Rituximab (RTX), the anti\u2010CD20 monoclonal antibody, has recently shown efficacy in many autoimmune diseases. In SSc\u2010ILD, RTX is also considered to be one of the novel treatment candidates. However, studies of SSc\u2010ILD in Japanese treated with RTX have only a few case reports. Therefore, in this study, we retrospectively compared nine patients treated with RTX and 30 patients treated with CYC to investigate the efficacy of RTX treatment for Japanese anti\u2010topoisomerase I\u2010positive SSc\u2010ILD patients. At the 24\u2010month evaluation, the improvement rates of percent predicted of forced vital capacity and percent predicted of diffusing capacity of the lung carbon monoxide in the RTX\u2010treated group were significantly higher than those in the CYC\u2010treated group (20.6\u00a0\u00b1\u00a08.8% vs 1.1\u00a0\u00b1\u00a03.9%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05 and 34.0\u00a0\u00b1\u00a06.0% vs \u22121.5\u00a0\u00b1\u00a02.8%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01, respectively). In addition, skin thickness scores also showed a marked improvement from 13.5 points before the start of treatment to 5.8 points after 24\u00a0months by RTX therapy (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). These results suggest that RTX treatment is more effective for Japanese SSc\u2010ILD patients than CYC treatment. In the future, it is expected that large\u2010scale clinical trials will show the usefulness of RTX treatment for SSc\u2010ILD.<\/jats:p>","DOI":"10.1111\/1346-8138.15079","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T04:35:46Z","timestamp":1568090146000},"page":"1006-1013","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti\u2010topoisomerase I\u2010positive systemic sclerosis\u2010associated interstitial lung disease"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-1513","authenticated-orcid":false,"given":"Satoshi","family":"Ebata","sequence":"first","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemichi","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayakazu","family":"Sumida","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31139"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.149"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-013-9532-y"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096677"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"e_1_2_6_11_1","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open\u2010label study","volume":"35","author":"B\u00e9rezn\u00e9 A","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_1","first-page":"w14030","article-title":"Cyclophosphamide: as bad as its reputation? Long\u2010term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases","volume":"144","author":"Dan D","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.01.003"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.04.006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22847"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.11.6635"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.1.1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-015-0016-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu463"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1102963"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0104"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker290"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24249"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2965"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.013"},{"issue":"2","key":"e_1_2_6_31_1","first-page":"S17","article-title":"Effect of long\u2010term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis D","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.095463"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120778"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050187"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.3.715"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12030"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21716"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21968"},{"key":"e_1_2_6_41_1","first-page":"122","article-title":"The significance of interleukin\u20106 and C\u2010reactive protein in systemic sclerosis: a systematic literature review","volume":"31","author":"Muangchant C","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518760955"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23540"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016659"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.01.002"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11501"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000584"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214816"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.03.004"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3435"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.177.12.1397a"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.15079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T22:30:32Z","timestamp":1694039432000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.15079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/1346-8138.15079"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.15079","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"2019-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}